Quality appraisal of clinical evidence-based guidelines for diabetes in children and adolescents based on AGREE Ⅱ
DING Xiangyu1 WANG Jianxin2 ZHANG Guying1 LIU Yanhui1
1.Department of Pharmacy, Children′s Hospital of Hebei Province, Hebei Province, Shijiazhuang 050031, China;
2.Department of Pharmacy, the First Hospital of Hebei Medical University, Hebei Province, Shijiazhuang 050030, China
Abstract：Objective To evaluate the quality of clinical evidence-based guidelines for diabetes in children and adolescents, and to compare the differences in drug treatment between the guidelines, so as to provide references for clinicians and pharmacists. Methods China National Knowledge Infrastucture, Wanfang Data, VIP, CBM database, PubMed database, Excerpta Medica Database and relevant websites such as medlive.cn, GIN, AAP, NGC, NICE were searched by computer ranged from the beginning of the database to the end of December 2018. The Appraisal of Guidelines for Research & Evaluation (AGREEⅡ) instrument was used to evaluate the quality of clinical evidence-based guidelines for diabetes in children and adolescents for the sake of the comparison of recommendations on drug therapy. Results A total of four guidelines were included respectively from the United States AAP, International ISPAD, Malaysia MaHTAS and the United Kingdom NICE. The overall quality of the guidelines was relatively high. Among these guidelines, the quality of MaHTAS and NICE were rated A, while the quality of AAP and ISPAD guidelines were rated B. In all fields, “clarity of presentation” and “scope and purpose” scored well，but the scores of “rigor of development” and “applicability” were relatively low. The drug recommendations in each guideline were basically consistency. Conclusion The quality of inclusion guidelines is relatively high. There is still a lack of evidence-based clinical guidelines for children with diabetes in China. It is suggested that evidence-based methods should be adopted to formulate evidence-based guidelines in line with China′s national conditions so as to provide a basis for the treatment of diabetic children in China.
丁翔宇1 王建欣2 张古英1 刘艳辉1. 儿童青少年糖尿病临床循证指南质量AGREEⅡ评价情况[J]. 中国医药导报, 2019, 16(27): 65-68.
DING Xiangyu1 WANG Jianxin2 ZHANG Guying1 LIU Yanhui1. Quality appraisal of clinical evidence-based guidelines for diabetes in children and adolescents based on AGREE Ⅱ. 中国医药导报, 2019, 16(27): 65-68.
[1] IDF Diabetes Atlas [M]. 8th ed. Brussels，Belgium：International Diabetes Federation，2017.
[2] Zeitler P，Arslanian S，Fu JF. Type 2 diabetes mellitus in youth [J]. Pediatr Diabetes，2018，19（suppl 27）：26-28.
[3] Farsani SF，Van Der Aa M，Van Der Vorst M，et al. Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents：a systematic review and evaluation of methodological approaches [J]. Diabetologia，2013， 56（7）：1471-1488.
[4] 胡志强，张伶俐，李幼平，等.新生儿细菌性脑膜炎药物治疗循证指南的系统评价[J].中国循证医学杂志，2015， 15（1）：28-35.
[5] 陈尹，胡世莲，李幼平，等.全球药物干预治疗单纯性高血压指南的系统评价[J].中国循证医学杂志，2012，12（10）：1180-1194.
[6] 归舸，蒋璐灿，张伶俐.全球现有儿童特发性血小板减少性紫癜指南的循证评价[J].中国药房，2018，29（4）：541-546.
[7] Copeland KC，Silverstein J，Moore KR，et al. Management of newly diagnosed type 2 diabetes mellitus （T2DM） in children and adolescents [J]. Pediatrics，2013，131（2）：364-382.
[8] Acerini CL，Codner E，Craig ME，et al. ISPAD clinical practice consensus guidelines 2018 [J]. Pediatr Diabetes，2018， 19（Suppl 12）：1-338．
[9] Management of Type 1 Diabetes Mellitus in Children & Adolescents. Malaysia Health Technology Assessment Section （MaHTAS） [EB/OL]. 2015. http：//www.acadmed.org.my.
[10] Diabetes （type 1 and type 2） in children and young people：diagnosis and management（NG18）. NICE guideline Published [EB/OL]. 2015. nice.org.uk/guidance/ng18.
[11] Redon I，Beltrand J，Martin D，et al. Changes in insulin therapy regimens over 10 yr in children and adolescents with type 1 diabetes attending diabetes camps [J]. Pediatr Diabetes，2014，15（5）：329-335.
[12] Rendell M. Premix insulins in type 1 diabetes：the coming of degludec/aspart [J]. Expert Opin Drug Metab Toxicol，2019，15（4）：341-348.
[13] Smith JD，Mills E，Carlisle SE. Treatment of pediatric type 2 diabetes [J]. Ann Pharmacother，2016，50（9）：768-777.
[14] Zeitler P，Hirst K，Pyle L，et al. TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes [J]. N Engl J Med，2012，366（24）：2247-2256.
[15] Food and Drug Administration. FDA drug safety communication：FDA eliminates the Risk Evaluation and Mitigation Strategy （REMS） for rosiglitazone-containing diabetes medicines [EB/OL]. 2016. http：//www.fda.gov/Drugs/DrugSafety/ucm476466.htm.
[16] Leonard CE，Bilker WB，Brensinger CM，et al. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics [J]. Clin Pharmacol Ther，2016， 99（5）：538-547.
[17] Hellman B，Dansk H，Grapengiesser E. Sulfonylurea blockade of KATP channels unmasks a distinct type of glucose-induced Ca2+ decrease in pancreatic β-cells [J]. Pancreas，2017，46（4）：467-475.
[18] 中华医学会儿科学分会内分泌遗传代谢学组《中华儿科杂志》编辑委员会.儿童及青少年糖尿病的胰岛素治疗指南（2010年版）[J].中华儿科杂志，2010，48（6）：431-435.
[19] 中华医学会儿科学分会内分泌遗传代谢学组.儿童青少年２型糖尿病诊治中国专家共识[J].中华儿科杂志，2017，55（6）：404-410.
[20] 张伶俐，李幼平，张川.中国儿童临床指南现状分析及循证临床指南评价[J].中国循证医学杂志，2011，11（9）：991-999.
2019, Vol. 16 
京公网安备 11010502046598号